摘要
目的评价唑来膦酸联合泰索帝治疗晚期非小细胞肺癌骨转移的疗效及安全性。方法41例晚期非小细胞肺癌骨转移患者随机分为唑来膦酸联合泰索帝(A组)及单用唑来膦酸(B组)治疗,对两组疗效进行分析比较。结果A组骨痛缓率、生存质量改善率略好于B组(P>0.05),毒副作用差异无显著性。A组骨转移灶修复率52.4%(11/29),B组20.0%(4/20),差异有显著性(P<0.05)。结论唑来膦酸联合泰索帝治疗晚期非小细胞肺癌骨转移有较好的治疗用,毒性可耐受。
Objective To investigate the efficacy and safety of zoledronic acid combined with Docetaxel Dili treatment for Advanced Non-small Cell Lung Cancer with Bone Metastases and negative hormone receptors.Methods Fifty-eight breast caner patients with multiple bone metastases were randomized divided intotwo groups： Group A （zoledronic acid plus chemotherapy group） and group B （zoledronic acid alone group）.The effect was compared in two groups.Results Relief pain of bone, improve quality of life and toxicity between two groups showed no significant difference. The response rate of bone metastases was 55.2% （16/29） in group A, it was significantly higher than that in group B,13.8%（4/29）. Conclusion Zoledronic acid combined with chemotherapy for breast cancer patients with bone metastases and negative hormone receptors shows a better efficacy, and the toxicity is well tolerated.
出处
《医学信息》
2008年第10期1833-1835,共3页
Journal of Medical Information
关键词
非小细胞肺癌
骨转移
药物疗法
唑来膦酸
泰素帝
breast neoplasms
bone metastases
chemotherapy
zoledronic acid
Docetaxel Dili
